INVIVYD INC. - COMMON

Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer

23 Feb 2022 15:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces ADG20 Development Plans and Pipeline Updates

22 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces CEO Succession Plan

18 Feb 2022 18:33:28 By Nasdaq GlobeNewswire

Adagio Therapeutics Summarizes ADG20 Neutralizing Activity Against SARS-CoV-2 Variants and Outlines Initiatives to Address Omicron

12 Jan 2022 15:56:55 By Nasdaq GlobeNewswire

Adagio Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

06 Jan 2022 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant

14 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro

29 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces Expansion of Management Team and Board of Directors to Support Rapid Advancement and Commercial Readiness of ADG20 for COVID-19

22 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results

15 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics to Participate in Upcoming Investor Conferences

10 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants

19 Oct 2021 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19

29 Sep 2021 05:30:00 By Nasdaq GlobeNewswire

Adagio Therapeutics to Participate in the Guggenheim 2nd Annual Vaccines & Infectious Day Conference

29 Sep 2021 05:30:00 By Nasdaq GlobeNewswire